PF-Atlas › Clinical Trials › NCT00982930

Open Label Extension to Bridging Study CTBM100C2303

Tobramycin inhalation powder · Phase 3

Registry ID
NCT00982930
Phase
Phase 3
Status
Completed
Drug / intervention
Tobramycin inhalation powder
Sponsor
Novartis Pharmaceuticals
Start
2009-08-12
Enrollment
55
Locations
2

About this trial

This was an open-label, single arm (uncontrolled) study in participants suffering from cystic fibrosis, who had completed their study participation in CTBM100C2303 (all visits) and who were proven infected with Pseudomonas aeruginosa (P. aeruginosa) at enrollment into CTBM100C2303.

View NCT00982930 on ClinicalTrials.gov →

Explore related

All Tobramycin inhalation powder trialsAll IPF trials

Related trials

Tobramycin Inhalation Powder — NCT01844778Tobramycin Inhalation Powder — NCT00125346
Medical disclaimer. This page summarizes public trial data for NCT00982930 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.